Pfizer targets Omicron variant with new vaccine trial
Pfizer and BioNTech are working on a trial to test a modified COVID-19 vaccine aimed at targeting the Omicron variant. Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center, joined CBS News to discuss the latest on the pandemic, including why the FDA has halted use of two monoclonal antibody treatments that don't work well against Omicron.